Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
36 results about "Smac mimetics" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Smac mimetics are a new class of cancer therapeutics with great potential to overcome the limitations of current anticancer therapies. Smac mimetics are generally well tolerated and have demonstrated rapid suppression of their target (the IAPs), activation of apoptosis and anti-tumour activity.
Dimeric small molecule potentiators of apoptosis
Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Dimeric IAP inhibitors
ActiveUS7517906B2High sensitivityAccelerated deathOrganic active ingredientsBiocideSmac mimeticsTopoisomerase inhibitor
Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac / DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inhibitors, NSAIDs, taxanes and platinum containing compounds use broader language
Owner:MEDIVIR AB
Bivalent SMAC mimetics and the uses thereof
ActiveUS20080089896A1Toxic reductionMore tolerableBiocideOrganic chemistrySmac mimeticsSensitized cell
The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Dimeric IAP inhibitors
ActiveUS20060194741A1Increased cell deathIncreased apoptotic activityBiocideOrganic active ingredientsSmac mimeticsApoptosis
Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac / DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of LAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inbhibitors, NSAIDs, taxanes and platinum containing compounds use broader language
Owner:MEDIVIR AB
Dimeric small molecule potentiators of apoptosis
Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Conformationally Constrained Smac Mimetics and the Uses Thereof
ActiveUS20080269140A1High expressionToxic reductionDipeptide ingredientsTripeptide ingredientsSmac mimeticsSensitized cell
The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Bivalent smac mimetics and the uses thereof
ActiveUS20090123480A1Toxic reductionMore tolerableBiocideOrganic chemistrySmac mimeticsSensitized cell
The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Conformationally Constrained Smac Mimetics And The Uses Thereof
InactiveUS20080132485A1Toxic reductionMore tolerableBiocideOrganic chemistrySmac mimeticsSensitized cell
The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Dimeric iap inhibitors
InactiveUS20080020986A1Remove inhibitionMultiple EffectsAntibacterial agentsBiocideSmac mimeticsDimer
Owner:TETRALOGIC BIRINAPANT UK
Conformationally constrained Smac mimetics and the uses thereof
InactiveUS7674787B2Toxic reductionMore tolerableBiocideOrganic chemistrySmac mimeticsSensitized cell
Owner:RGT UNIV OF MICHIGAN
Conformationally constrained Smac mimetics and the uses thereof
ActiveUS7932382B2Toxic reductionMore tolerableAntineoplastic agentsHeterocyclic compound active ingredientsSmac mimeticsSensitized cell
Owner:RGT UNIV OF MICHIGAN
Bivalent Smac mimetics and the uses thereof
Owner:RGT UNIV OF MICHIGAN
Dimeric Smac Mimetics
InactiveUS20110195043A1Reduce cell deathReduce cell proliferationAntipyreticAnalgesicsSmac mimeticsDisease
The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.
Owner:JOYANT PHARMA INC
Dimeric IAP inhibitors
InactiveUS7985735B2Remove inhibitionMultiple EffectsAntibacterial agentsBiocideSmac mimeticsStereochemistry
Owner:TETRALOGIC BIRINAPANT UK
SMAC Mimetic
Owner:MEDIVIR AB
Smac Mimetic Therapy
InactiveUS20140303090A1Dipeptide ingredientsMicrobiological testing/measurementSmac mimeticsCancer research
A Smac mimetic therapy wherein the Smac mimetic is selected and developed based at least in part on its poor inhibition of XIAP-dependent processes.
Owner:WALTER & ELIZA HALL INST OF MEDICAL RES +1
Heteroaryl-substituted bicyclic smac mimetics and the uses thereof
ActiveUS20110046189A1High expressionMore tolerableBiocideOrganic chemistrySmac mimeticsSensitized cell
The invention relates to heteroaryl-substituted bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Dimeric IAP inhibitors
Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac / DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes. In various embodiments of the invention the Smac mimetics of the invention are combined with chemotherapeutic agents, including, but not limited to topoisomerase inhibitors, kinase inbhibitors, NSAIDs, taxanes and platinum containing compounds use broader language.
Owner:梅迪维尔有限公司
IAP inhibitors
InactiveUS8143426B2Remove inhibitionMultiple EffectsBiocideDipeptide ingredientsSmac mimeticsChemistry
Owner:TETRALOGIC BIRINAPANT UK
Diazo bicyclic smac mimetics and the uses thereof
ActiveUS20100273812A1Toxic reductionMore tolerableBiocideSenses disorderSmac mimeticsSensitized cell
The invention relates to diazo bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Diazo bicyclic Smac mimetics and the uses thereof
The invention relates to diazo bicyclic mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.
Owner:RGT UNIV OF MICHIGAN
Bivalent SMAC mimetics and the uses thereof
Owner:RGT UNIV OF MICHIGAN
Bivalent diazo bicyclic Smac mimetics and the uses thereof
The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The invention also relates to the use of bivalent diazo bicyclic Smac mimetics for inducing or sensitizing cells to the induction of apoptotic cell death. Thus, compounds of the invention are useful in the treatment, amelioration, or prevention of hyperproliferative diseases such as cancer.
Owner:RGT UNIV OF MICHIGAN
Bivalent diazo bicyclic smac
The invention relates to diazo bicyclic Smac mimetics that are tethered through a covalent linker to give a bivalent species. Bivalent diazo bicyclic Smac mimetics function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs). The invention also relates to the use of bivalent diazo bicyclic Smac mimetics for inducing or sensitizing cells to the induction of apoptotic cell death. Thus, compounds of the invention are useful in the treatment, amelioration, or prevention of hyperproliferative diseases such as cancer.
Owner:RGT UNIV OF MICHIGAN
Immunomodulation by iap inhibitors
ActiveUS20110135691A1Improving immunogenicityIncrease in activation of cellAntibacterial agentsBiocideSmac mimeticsImmunomodulations
The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
Owner:DANA FARBER CANCER INST INC +1
Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
Owner:RGT UNIV OF MICHIGAN
Method of Treating Intracellular Infection
The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.
Owner:WALTER & ELIZA HALL INST OF MEDICAL RES
Dimeric Smac mimetics
The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.
Owner:JOYANT PHARMA INC
Method of Treatment
Owner:TETRALOGIC BIRINAPANT UK +1
Smac mimetec
Owner:MEDIVIR AB
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com